AUTHORS
Siyu Chen, Cheng Zhang, MD2, Hai Yi, MD,PhD3, Jianchuan Deng, PHD4, Yi Yang5, Xu Tan6, Guo Chen7, Li Li8, Zhang Mengyun9, Bo Liu10, Yilan Liu, MD11, Shen Yan12, Hongxia Chen13, Wen Qin, MD14, Hong Liu15, Xi Zhang, MD16
AFFILIATIONS
1 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
2 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
3 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
4 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
5 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
6 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
7 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
8 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
9 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
10 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
11 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
12 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
13 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
14 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
15 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
16 Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, China
ABSTRACT
Background: Improving the MRD-negative conversion rate in a safe manner is important for adult patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (Ph-negative B-ALL), while conventional pediatric-inspired induction regimens achieve MRD negativity in only approximately 40%–50% with sever treatment-related toxicities, including severe infections, bleeding, and organ dysfunction. The efficacy and safety of chemotherapy-free induction therapy with Blinatumomab plus Lisaftoclax Tablets in adults with Ph-negative B-ALL were never reported.
Methods: This is a multicenter, randomized, controlled, open-label, prospective study. The key inclusion criteria were: (1) 18-65 years old; (2) diagnosed with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia according to 2016 WHO classification; (3) achieved over 2 points in Eastern Cooperative Oncology Group performance status. Lisaftoclax Tablets was initiated at 200 mg in d1, and continued with 400 mg in d2, and 600 mg from d3 to d7 followed by Intravenous injection of Blinatumomab with 9 μg from d8 to d10 and 28 μg from d 11 to d30 in the experimental group. The consolidation therapy was performed on the patients in control group. Patients with a high leukemic burden received glucocorticoid prephase therapy until the peripheral white blood cell count had decreased to <50 × 10?/L before induction therapy was initiated. The primary endpoint was the rate of MRD negativity at the end of induction, defined using a threshold of 10?4.
Results: Between July 2025 and May 2026, 15 patients were enrolled, including eight in the experimental group and seven in the control group. In the experimental group, the median age was 43 years (range, 20–55 years); six patients were female and two patients were male. One patient harbored a TP53 mutation, and four patients had high-risk cytogenetic features, defined as KMT2A rearrangement or a complex karyotype. In the control group, the median age was 29 years (range, 24–41 years); three patients were female and four patients were male. One patient harbored an ETV6::TBL1XR1 fusion, and two patients had high-risk cytogenetic features.
Regarding treatment efficacy, in the experimental group, six of eight patients achieved CR/CRi after completing Lisaftoclax Tablets treatment and before the initiation of blinatumomab; after completion of induction therapy, seven of eight patients attained CR/CRi, and all seven responders were MRD-negative by both flow cytometry (FC) and next-generation sequencing (NGS). In the control group, five of seven patients achieved CR/CRi after induction therapy completion, among whom four patients showed FC-MRD negativity and three patients exhibited NGS-MRD negativity.
Regarding safety outcomes, the most common adverse events were thrombocytopenia, leukopenia, and neutropenia, occurring in 37.5% versus 85.7%, 37.5% versus 71.4%, and 50.0% versus 85.7% of patients in the experimental and control groups, respectively. In the experimental group, four patients developed grade one cytokine release syndrome, which resolved after dexamethasone intervention without affecting subsequent treatment; in the control group, two patients developed pulmonary infection, and four patients developed anemia. Regarding blood product utilization, one patient in the experimental group received a platelet transfusion of 200 mL, and two patients received packed red blood cell transfusions, with a median volume of 400 mL (2 U; range, 200–800 mL). Patients receiving blood products in the experimental group already exhibited thrombocytopenia and anemia at baseline; therefore, blood transfusion support was administered prior to treatment, but no further blood product transfusions were administered during subsequent induction therapy. In the control group, four patients received platelet transfusions, with a median volume of 600 mL (3 U; range, 200–1,000 mL), and five patients received packed red blood cell transfusions, with a median volume of 1,200 mL (6 U; range, 400–2,000 mL). No treatment-related deaths occurred in either group.
Conclusions:
The chemotherapy-free induction regimen combining Blinatumomab with Lisaftoclax Tablets has achieved higher rates of complete remission (CR) and MRD-negative outcomes in adult patients with Ph-negative B-cell acute lymphoblastic leukemia, while also significantly reduced hematological toxicity and the need for blood product transfusions.
DISCLOSURES
Siyu Chen: No relevant conflicts of interest to declare.